Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: Five-year results of a prospective randomized multicenter clinical trial

Carol Devine; Charles McCollum

doi:10.1016/j.jvs.2004.08.033

Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: Five-year results of a prospective randomized multicenter clinical trial

Research output: Contribution to journal › Article › peer-review

Abstract

Dacron was largely abandoned for femoropopliteal bypass 30 years ago, because better patency rates were achieved with saphenous vein. Despite the range of potential prosthetics, polytetrafluoroethylne (PTFE) clearly predominates in current femoropopliteal practice. We compared heparin-bonded Dacron (HBD) with PTFE in a randomized multicenter clinical trial. Over 28 months, 209 patients (179 above-knee disease, 30 below-knee disease) were randomized to receive HBD (n = 106) or PTFE (n = 103) grafts. Aspirin, 300 mg/d, was started before surgery, and was continued if tolerated. At follow-up for a minimum of 5 years (mean, 76 months; range, 60-89 months), 37 patients (17.7%) had died with patent grafts and 121 (58%) grafts were occluded. Primary patency rate, measured with Kaplan-Meier survival analysis, was 46% (95% confidence interval [CI], 35%-57%) at year 5 for HBD, compared with 35% for PTFE (CI, 25%-45%; P

Original language	English
Pages (from-to)	924-931
Number of pages	7
Journal	Journal of vascular surgery
Volume	40
Issue number	5
DOIs	https://doi.org/10.1016/j.jvs.2004.08.033
Publication status	Published - Nov 2004

Keywords

Adult
Aged
Aged, 80 and over
Anastomosis, Surgical
Aortography
radiography: Arterial Occlusive Diseases
Blood Vessel Prosthesis
adverse effects: Blood Vessel Prosthesis Implantation
Coated Materials, Biocompatible
Female
surgery: Femoral Artery
Follow-Up Studies
Graft Survival
Great Britain
pharmacology: Heparin
Humans
Male
Middle Aged
radiography: Peripheral Vascular Diseases
Polyethylene Terephthalates
Polytetrafluoroethylene
surgery: Popliteal Artery
Probability
Prospective Studies
Prosthesis Design
Reference Values
Risk Assessment
Treatment Outcome
physiology: Vascular Patency

Access to Document

10.1016/j.jvs.2004.08.033

Cite this

@article{78bf980679a9439fba461546b26b46be,

title = "Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: Five-year results of a prospective randomized multicenter clinical trial",

abstract = "Dacron was largely abandoned for femoropopliteal bypass 30 years ago, because better patency rates were achieved with saphenous vein. Despite the range of potential prosthetics, polytetrafluoroethylne (PTFE) clearly predominates in current femoropopliteal practice. We compared heparin-bonded Dacron (HBD) with PTFE in a randomized multicenter clinical trial. Over 28 months, 209 patients (179 above-knee disease, 30 below-knee disease) were randomized to receive HBD (n = 106) or PTFE (n = 103) grafts. Aspirin, 300 mg/d, was started before surgery, and was continued if tolerated. At follow-up for a minimum of 5 years (mean, 76 months; range, 60-89 months), 37 patients (17.7%) had died with patent grafts and 121 (58%) grafts were occluded. Primary patency rate, measured with Kaplan-Meier survival analysis, was 46% (95% confidence interval [CI], 35%-57%) at year 5 for HBD, compared with 35% for PTFE (CI, 25%-45%; P",

keywords = "Adult, Aged, Aged, 80 and over, Anastomosis, Surgical, Aortography, radiography: Arterial Occlusive Diseases, Blood Vessel Prosthesis, adverse effects: Blood Vessel Prosthesis Implantation, Coated Materials, Biocompatible, Female, surgery: Femoral Artery, Follow-Up Studies, Graft Survival, Great Britain, pharmacology: Heparin, Humans, Male, Middle Aged, radiography: Peripheral Vascular Diseases, Polyethylene Terephthalates, Polytetrafluoroethylene, surgery: Popliteal Artery, Probability, Prospective Studies, Prosthesis Design, Reference Values, Risk Assessment, Treatment Outcome, physiology: Vascular Patency",

author = "Carol Devine and Charles McCollum",

year = "2004",

month = nov,

doi = "10.1016/j.jvs.2004.08.033",

language = "English",

volume = "40",

pages = "924--931",

journal = "Journal of vascular surgery",

issn = "0741-5214",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: Five-year results of a prospective randomized multicenter clinical trial

AU - Devine, Carol

AU - McCollum, Charles

PY - 2004/11

Y1 - 2004/11

N2 - Dacron was largely abandoned for femoropopliteal bypass 30 years ago, because better patency rates were achieved with saphenous vein. Despite the range of potential prosthetics, polytetrafluoroethylne (PTFE) clearly predominates in current femoropopliteal practice. We compared heparin-bonded Dacron (HBD) with PTFE in a randomized multicenter clinical trial. Over 28 months, 209 patients (179 above-knee disease, 30 below-knee disease) were randomized to receive HBD (n = 106) or PTFE (n = 103) grafts. Aspirin, 300 mg/d, was started before surgery, and was continued if tolerated. At follow-up for a minimum of 5 years (mean, 76 months; range, 60-89 months), 37 patients (17.7%) had died with patent grafts and 121 (58%) grafts were occluded. Primary patency rate, measured with Kaplan-Meier survival analysis, was 46% (95% confidence interval [CI], 35%-57%) at year 5 for HBD, compared with 35% for PTFE (CI, 25%-45%; P

AB - Dacron was largely abandoned for femoropopliteal bypass 30 years ago, because better patency rates were achieved with saphenous vein. Despite the range of potential prosthetics, polytetrafluoroethylne (PTFE) clearly predominates in current femoropopliteal practice. We compared heparin-bonded Dacron (HBD) with PTFE in a randomized multicenter clinical trial. Over 28 months, 209 patients (179 above-knee disease, 30 below-knee disease) were randomized to receive HBD (n = 106) or PTFE (n = 103) grafts. Aspirin, 300 mg/d, was started before surgery, and was continued if tolerated. At follow-up for a minimum of 5 years (mean, 76 months; range, 60-89 months), 37 patients (17.7%) had died with patent grafts and 121 (58%) grafts were occluded. Primary patency rate, measured with Kaplan-Meier survival analysis, was 46% (95% confidence interval [CI], 35%-57%) at year 5 for HBD, compared with 35% for PTFE (CI, 25%-45%; P

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Anastomosis, Surgical

KW - Aortography

KW - radiography: Arterial Occlusive Diseases

KW - Blood Vessel Prosthesis

KW - adverse effects: Blood Vessel Prosthesis Implantation

KW - Coated Materials, Biocompatible

KW - Female

KW - surgery: Femoral Artery

KW - Follow-Up Studies

KW - Graft Survival

KW - Great Britain

KW - pharmacology: Heparin

KW - Humans

KW - Male

KW - Middle Aged

KW - radiography: Peripheral Vascular Diseases

KW - Polyethylene Terephthalates

KW - Polytetrafluoroethylene

KW - surgery: Popliteal Artery

KW - Probability

KW - Prospective Studies

KW - Prosthesis Design

KW - Reference Values

KW - Risk Assessment

KW - Treatment Outcome

KW - physiology: Vascular Patency

U2 - 10.1016/j.jvs.2004.08.033

DO - 10.1016/j.jvs.2004.08.033

M3 - Article

SN - 0741-5214

VL - 40

SP - 924

EP - 931

JO - Journal of vascular surgery

JF - Journal of vascular surgery

IS - 5

ER -

Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: Five-year results of a prospective randomized multicenter clinical trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this